- ImmuPharma has selected Thermo Fisher Scientific as the CDMO to support pharmaceutical development and IND-enabling preparation for its Kapiglucagon program.
- The collaboration will support development of Kapiglucagon, a proprietary glucagon prodrug for Type 1 diabetes applications, as the company advances the program toward clinical development.
ImmuPharma plc has selected Thermo Fisher Scientific as the contract development and manufacturing organization (CDMO) for its Kapiglucagon program. The agreement supports the next stages of pharmaceutical development and IND-enabling preparation for the company’s proprietary glucagon prodrug.
Kapiglucagon is being developed for Type 1 diabetes applications, with a focus on addressing the physicochemical limitations of native glucagon. According to ImmuPharma, the program is designed to improve solubility and formulation stability and may have applications in dual-hormone artificial pancreas systems and other glucagon-based therapeutic settings.
The appointment of Thermo Fisher will support the chemistry, manufacturing, and controls (CMC) activities required as the program progresses toward clinical development. The CDMO will contribute to the pharmaceutical development and contract manufacturing work needed for IND-enabling preparation.
ImmuPharma has previously stated that it plans to pursue an accelerated development strategy for Kapiglucagon, including evaluating a 505(b)(2) regulatory pathway. The company also said the program is supported by a recently approved funding initiative intended to advance the asset over the next two years.
“We are pleased to select Thermo Fisher as DP CDMO for the Kapiglucagon program. This represents an important step in strengthening the CMC foundation of the program as we continue to advance Kapiglucagon toward clinical development.”
Dr. Sébastien Goudreau, Chief Scientific Officer of ImmuPharma
